Northern Trust
GLUE icon

Northern Trust’s Monte Rosa Therapeutics GLUE Stock Holding History

Northern Trust’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8M Sell
652,087
-174,537
-21% -$3.3M ﹤0.01% 1933
2026
Q1 		$13.6M Buy
826,624
+129,590
+19% +$2.48M ﹤0.01% 1906
2025
Q4 		$10.9M Sell
697,034
-43,650
-6% -$588K ﹤0.01% 2033
2025
Q3 		$5.49M Sell
740,684
-20,735
-3% -$110K ﹤0.01% 2448
2025
Q2 		$3.43M Buy
761,419
+388,212
+104% +$1.73M ﹤0.01% 2690
2025
Q1 		$1.73M Sell
373,207
-3,757
-1% -$23K ﹤0.01% 2996
2024
Q4 		$2.62M Buy
376,964
+18,391
+5% +$138K ﹤0.01% 2862
2024
Q3 		$1.9M Buy
358,573
+64,377
+22% +$325K ﹤0.01% 3036
2024
Q2 		$1.1M Buy
294,196
+3,742
+1% +$19.1K ﹤0.01% 3200
2024
Q1 		$2.05M Buy
290,454
+5,520
+2% +$32.7K ﹤0.01% 2948
2023
Q4 		$1.61M Sell
284,934
-159,028
-36% -$624K ﹤0.01% 3107
2023
Q3 		$2.13M Buy
443,962
+15,473
+4% +$99.6K ﹤0.01% 2905
2023
Q2 		$2.94M Buy
428,489
+177,962
+71% +$1.15M ﹤0.01% 2792
2023
Q1 		$1.95M Sell
250,527
-4,584
-2% -$31.9K ﹤0.01% 2946
2022
Q4 		$1.94M Buy
255,111
+6,961
+3% +$58K ﹤0.01% 3015
2022
Q3 		$2.03M Buy
248,150
+24,385
+11% +$224K ﹤0.01% 3003
2022
Q2 		$2.16M Buy
223,765
+4,027
+2% +$40.5K ﹤0.01% 3015
2022
Q1 		$3.08M Buy
219,738
+111,573
+103% +$1.55M ﹤0.01% 2867
2021
Q4 		$2.21M Buy
108,165
+4,168
+4% +$87.3K ﹤0.01% 3176
2021
Q3 		$2.32M Buy
+103,997
New +$2.98M ﹤0.01% 3213

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Northern Trust's GLUE Position: Q2 2026 in Review

Northern Trust reduced its Monte Rosa Therapeutics (GLUE) stake by 21% in Q2 2026, selling an estimated $3.3M and leaving 652,087 shares worth $15.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1933.

Northern Trust first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Northern Trust held 652,087 shares of Monte Rosa Therapeutics worth $15.8M as of Q2 2026.
  • Northern Trust sold 174,537 Monte Rosa Therapeutics shares in Q2 2026, an estimated $3.3M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1933 holding.
  • Northern Trust first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.